

Bertrand Pourroy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3538959/bertrand-pourroy-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22

papers

435

citations

12

h-index

20

g-index

23

ext. papers

496

ext. citations

3.5

avg, IF

2.53

L-index

#	Paper	IF	Citations
22	Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Française de Pharmacie Oncologique [SFPO]) Guidelines. <i>JCO Oncology Practice</i> , 2020 , 16, e1282-e1290	2.3	3
21	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). <i>Cancer Treatment Reviews</i> , 2020 , 88, 102063	14.4	20
20	Availability of Morphine Oral Solution for Childhood Cancer Patients in Low-Income Countries: Compounding and Stability Study in a Cote d'Ivoire University Teaching Hospital. <i>Journal of Pain and Symptom Management</i> , 2020 , 59, e10-e13	4.8	1
19	Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France. <i>European Journal of Cancer Care</i> , 2017 , 26, e12752	2.4	6
18	Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 1217-1218	2.2	
17	A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. <i>Scientific Reports</i> , 2017 , 7, 2714	4.9	32
16	Safety of chemotherapy prescription and production software: proposal of specific guidelines to test new versions. <i>European Journal of Hospital Pharmacy</i> , 2017 , 24, 193	1.6	
15	Keeping sterile 0.9% sodium chloride, 5% dextrose, and lactated Ringers solutions for injection cold enough for dilution of decitabine in isolators. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 748-50	2.2	
14	Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. <i>International Journal of Pharmaceutics</i> , 2015 , 495, 956-62	6.5	0
13	Keeping sterile water for injection cold enough for reconstitution of azacitidine in isolators. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 180-1	2.2	1
12	Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 1288-91	2.2	3
11	Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?. <i>International Journal of Clinical Pharmacy</i> , 2014 , 36, 420-9	2.3	17
10	SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. <i>Annales Pharmaceutiques Françaises</i> , 2013 , 71, 376-89	1.3	18
9	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. <i>Pharmacogenomics</i> , 2012 , 13, 393-7	2.6	15
8	High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. <i>Anti-Cancer Drugs</i> , 2008 , 19, 267-73	2.4	36
7	Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. <i>Biochemistry</i> , 2007 , 46, 14899-906	3.2	30
6	Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. <i>Cancer Research</i> , 2006 , 66, 3256-63	10.1	76

5	Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 532-9	3.2	28
4	Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. <i>Anti-Cancer Drugs</i> , 2006 , 17, 181-7	2.4	17
3	Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1231-4	2.4	10
2	Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 212-8	3.2	19
1	Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. <i>FEBS Letters</i> , 2002 , 532, 256-60	3.8	100